Affinage

FOXA1

Hepatocyte nuclear factor 3-alpha · UniProt P55317

Length
472 aa
Mass
49.1 kDa
Annotated
2026-04-28
100 papers in source corpus 51 papers cited in narrative 50 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FOXA1 is a forkhead-family pioneer transcription factor that opens compacted chromatin at lineage-specific enhancers to license the binding of nuclear hormone receptors—including estrogen receptor (ER), androgen receptor (AR), and glucocorticoid receptor (GR)—thereby acting as a master determinant of hormone-dependent gene expression programs across epithelial tissues (PMID:21151129, PMID:24875621, PMID:23269278). FOXA1 targets stable, DNase-resistant nucleosomes through low nucleoplasmic diffusion and prolonged chromatin residence, with its intrinsically disordered regions forming condensates that dissolve condensed chromatin, while its chromatin-binding activity is positively regulated by LSD1-mediated demethylation and negatively regulated by SETD7-mediated methylation at K270 (PMID:37405916, PMID:38101414, PMID:32868907, PMID:37549269). Beyond chromatin opening, FOXA1 couples pioneering to active DNA demethylation by recruiting DNA repair machinery (POLB) and TET1 to target enhancers, and exerts context-dependent transcriptional repression through corepressors TLE3 and HDAC7 (PMID:27500525, PMID:27257062, PMID:31874106, PMID:19917725). Recurrent cancer mutations in FOXA1—wing-2 domain substitutions that alter DNA-motif preference and chromatin mobility, C-terminal truncations that inactivate TLE3-mediated repression, and structural rearrangements that drive overexpression—reprogram its cistrome to activate oncogenic or therapy-resistant transcriptional programs in prostate and breast cancers (PMID:31243372, PMID:31243370, PMID:32888433).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 2005 High

    Establishing that Foxa1 and Foxa2 have compensatory roles in lung epithelial morphogenesis—regulating Shh signaling, branching, and differentiation—provided the first in vivo evidence that FOXA1 controls tissue-specific developmental programs.

    Evidence Foxa1-null / Foxa2-conditional double-knockout mouse embryonic lung model with gene expression analysis

    PMID:15668254

    Open questions at the time
    • Relative individual contributions of FOXA1 vs FOXA2 to each target gene not resolved
    • No genome-wide chromatin occupancy data in this system
  2. 2009 High

    Demonstrating that FOXA1 forms a tripartite complex with ERα and HDAC7 at the RPRM promoter established that FOXA1 mediates hormone-dependent transcriptional repression, not just activation, through corepressor recruitment.

    Evidence Co-IP identifying FOXA1–ERα–HDAC7 complex, ChIP showing co-occupancy and H3K4me changes upon estrogen treatment

    PMID:19917725

    Open questions at the time
    • Genome-wide extent of FOXA1-HDAC7-mediated repression unknown
    • Structural basis of tripartite complex not determined
  3. 2010 High

    Genome-wide ChIP-seq demonstrated that nearly all ER–chromatin interactions depend on FOXA1, establishing FOXA1 as an obligate pioneer factor for ER signaling and showing this dependency persists in tamoxifen-resistant cells.

    Evidence FOXA1 siRNA knockdown with ER ChIP-seq and chromatin accessibility assays in MCF-7 and tamoxifen-resistant derivatives

    PMID:21151129

    Open questions at the time
    • Mechanism by which FOXA1 opens chromatin at ER sites not molecularly defined
    • Whether FOXA1 dependency of ER varies across breast cancer subtypes not addressed
  4. 2010 High

    Conditional Foxa1 knockout in the mammary gland showed FOXA1 is required for ERα expression and hormone-induced ductal invasion, placing FOXA1 hierarchically upstream of ERα in mammary lineage specification.

    Evidence Foxa1 conditional knockout mouse mammary gland with IHC and siRNA in breast cancer cell lines

    PMID:20501593

    Open questions at the time
    • Direct transcriptional mechanism by which FOXA1 controls ERα gene expression not defined
    • Whether FOXA1 loss can be bypassed during mammary development not tested
  5. 2014 High

    Reciprocal gain- and loss-of-function experiments revealed a dose-dependent dual role for FOXA1: facilitating AR binding at FKHD-adjacent half-AREs at normal levels, but sequestering AR at excessive levels—resolving why FOXA1 can both promote and inhibit AR activity.

    Evidence FOXA1 knockdown and overexpression with AR ChIP-seq in LNCaP prostate cancer cells

    PMID:24875621

    Open questions at the time
    • Quantitative threshold governing facilitator-to-inhibitor switch not established
    • In vivo relevance of dose-dependent model not confirmed
  6. 2014 High

    Identification of FOXA1 SUMOylation at K6, K267, and K389, and demonstration that SUMO modification retards FOXA1 nuclear mobility and modulates AR-coregulatory activity, revealed a post-translational regulatory layer controlling FOXA1 chromatin dynamics.

    Evidence SUMOylation assays, FRAP live imaging of mCherry-FOXA1, ChIP, and site-directed mutagenesis

    PMID:25127374

    Open questions at the time
    • SUMO E3 ligase responsible not identified
    • Genome-wide impact of SUMOylation on FOXA1 cistrome not mapped
  7. 2014 High

    Showing that BRCA1 loss enables EZH2/DNMT-mediated epigenetic silencing of FOXA1 explained why basal-like BRCA1-deficient breast cancers lack FOXA1 and ER expression.

    Evidence ChIP for H3K27me3 and DNA methylation at FOXA1 promoter, BRCA1/EZH2 knockdown, pharmacological inhibition in BRCA1-deficient cells

    PMID:25531315

    Open questions at the time
    • Whether FOXA1 re-expression is sufficient to convert basal to luminal identity not tested
    • Relative contributions of EZH2 vs DNMT silencing not quantified
  8. 2016 High

    Discovery that FOXA1 recruits DNA polymerase β (POLB) to mediate lineage-specific DNA demethylation, and separately induces and physically interacts with TET1 to demethylate enhancers, established that FOXA1 couples chromatin opening to active DNA demethylation through dual mechanisms.

    Evidence Co-IP of FOXA1–POLB and FOXA1–TET1, genome-wide methylome sequencing, bisulfite sequencing, ChIP-seq

    PMID:27257062 PMID:27500525

    Open questions at the time
    • Whether POLB and TET1 pathways act at the same or distinct loci not resolved
    • Kinetic ordering of demethylation relative to nucleosome opening unknown
  9. 2019 High

    Comprehensive functional classification of recurrent FOXA1 mutations in prostate cancer into three mechanistic classes—wing-2 mutations enhancing chromatin mobility, C-terminal truncations inactivating TLE3-mediated repression, and structural rearrangements driving overexpression—explained how diverse FOXA1 alterations convergently promote oncogenesis through distinct cistrome rewiring mechanisms.

    Evidence Aggregate genomic cohort analysis, live-cell imaging, ChIP-seq, organoid proliferation assays, and motif analysis across 14 mutant variants

    PMID:31243370 PMID:31243372

    Open questions at the time
    • Crystal structures of mutant FOXA1–DNA complexes not available
    • Whether mutation classes synergize in compound heterozygotes not tested
  10. 2019 High

    In vitro reconstitution showed FOXA1 differentially regulates TDG-mediated excision of 5-formylcytosine on nucleosomal substrates, providing biochemical proof that pioneer factor activity directly modulates active DNA demethylation through base excision repair.

    Evidence Reconstituted nucleosome arrays with chemically defined 5fC, TDG activity assay ± FOXA1

    PMID:31460763

    Open questions at the time
    • Whether this occurs at physiological FOXA1-bound enhancers in cells not demonstrated
    • Role of FOXA1 IDRs in this context not tested
  11. 2020 High

    Identification of LSD1 as the demethylase and SETD7 as the methyltransferase controlling FOXA1 methylation at K270 established a reversible methylation switch that directly tunes FOXA1 chromatin-binding capacity and downstream AR signaling.

    Evidence In vitro demethylation/methylation assays, K270 mutagenesis, ChIP-seq, xenograft models

    PMID:32868907 PMID:37549269

    Open questions at the time
    • Whether other lysine methyltransferases contribute to K270 methylation not excluded
    • Structural basis for how K270 methylation state alters DNA binding not resolved
  12. 2021 High

    Demonstrating that FOXA1 is reprogrammed from AR-associated to neuroendocrine regulatory elements by lineage transcription factors ASCL1 and NKX2-1 showed that FOXA1's cistrome is plastic and context-dependent, explaining its essential role in both adenocarcinoma and neuroendocrine prostate cancer.

    Evidence ChIP-seq in patient-derived xenografts and cell lines, FOXA1 knockdown in NEPC, ectopic TF expression

    PMID:33785741

    Open questions at the time
    • Direct physical interaction between FOXA1 and ASCL1/NKX2-1 not demonstrated
    • Whether FOXA1 reprogramming is reversible not tested
  13. 2022 High

    FOXA1 was shown to orchestrate alternative splicing in prostate cancer by transcriptionally controlling splicing factor expression (HNRNPK, SRSF1), extending its regulatory reach beyond classical enhancer/promoter control to post-transcriptional gene regulation.

    Evidence ChIP-seq, RNA-seq splicing analysis across 500 prostate cancer transcriptomes, FOXA1 knockdown

    PMID:36170835

    Open questions at the time
    • Whether FOXA1 directly participates in spliceosome complexes not tested
    • Functional impact of individual FOXA1-regulated splicing events not characterized
  14. 2023 High

    Single-molecule tracking revealed that FOXA1 achieves pioneer activity through low nucleoplasmic diffusion and long residence times at stable nucleosomes, and separately, reconstitution showed that its intrinsically disordered regions form condensates that dissolve condensed chromatin—providing biophysical mechanisms for pioneer factor function.

    Evidence Single-molecule live-cell imaging comparing FOXA1/SOX2/HNF4A; in vitro condensate assays with IDR deletions, ATAC-seq

    PMID:37405916 PMID:38101414

    Open questions at the time
    • Whether condensate formation is required for pioneer activity in vivo not proven
    • How IDR-mediated condensation coordinates with K270 methylation switch not addressed
  15. 2023 High

    O-GlcNAcylation of FOXA1 at C-terminal residues was shown to reshape its protein interactome by recruiting MeCP2, redirecting FOXA1 to adhesion gene loci and promoting metastasis—establishing nutrient-sensing post-translational modification as a cistrome-remodeling mechanism.

    Evidence Mass spectrometry, site-directed mutagenesis, Co-IP/interactome, ChIP-seq, in vivo metastasis assays

    PMID:37595040

    Open questions at the time
    • O-GlcNAc transferase regulation of FOXA1 modification in physiological conditions not characterized
    • Interplay between O-GlcNAcylation and other FOXA1 PTMs not examined
  16. 2024 High

    Covalent small molecules targeting C258 in the FOXA1 forkhead domain were shown to rapidly redistribute FOXA1 genomic binding by relaxing canonical DNA-motif preference, demonstrating chemical tractability of pioneer factor activity and providing a pharmacological tool for cistrome modulation.

    Evidence Chemical proteomics, covalent ligand synthesis, ChIP-seq, ATAC-seq, C258 mutagenesis

    PMID:39413792

    Open questions at the time
    • In vivo efficacy and selectivity of C258-targeting compounds not established
    • Whether C258 modification phenocopies specific cancer mutations not tested
  17. 2024 High

    NSD2 was identified as a requisite co-factor of the AR/FOXA1 neo-enhanceosome at tumor-specific chimeric FOXA1:AR motifs, with NSD2 loss disrupting >65% of the AR cistrome—revealing an epigenetic co-dependency for oncogenic enhancer activation.

    Evidence ChIP-seq, NSD2 CRISPR/siRNA/PROTAC, patient enhancer mapping

    PMID:39251788

    Open questions at the time
    • Whether NSD2 directly interacts with FOXA1 protein not shown
    • Therapeutic window for NSD2 targeting in FOXA1-driven cancers not defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the multiple post-translational modifications of FOXA1 (K270 methylation, K295 methylation, SUMOylation, O-GlcNAcylation, ubiquitination) are integrated combinatorially to specify distinct cistromes and transcriptional outputs in different cell lineages remains unresolved.
  • No systematic PTM crosstalk analysis performed
  • No high-resolution structure of full-length FOXA1 with IDRs
  • In vivo condensate dynamics and their relationship to pioneer activity and PTM state not characterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 8 GO:0003677 DNA binding 6 GO:0042393 histone binding 2
Localization
GO:0005634 nucleus 4 GO:0005694 chromosome 2
Pathway
R-HSA-74160 Gene expression (Transcription) 5 R-HSA-162582 Signal Transduction 4 R-HSA-1266738 Developmental Biology 3 R-HSA-4839726 Chromatin organization 3
Partners
ARCREB5ESR1LSD1POLBSTAT2TET1TLE3
Complex memberships
AR/FOXA1/NSD2 neo-enhanceosomeERα/FOXA1/HDAC7 repressive complexFOXA1/TLE3 corepressor complex

Evidence

Reading pass · 50 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2010 FOXA1 is a key determinant of estrogen receptor (ER) chromatin binding: nearly all ER-chromatin interactions and ER-dependent gene expression changes depend on FOXA1 presence, and FOXA1 influences genome-wide chromatin accessibility. In tamoxifen-resistant cells, ER binding is independent of ligand but still depends on FOXA1. CTCF was identified as an upstream negative regulator of FOXA1-chromatin interactions. ChIP-seq, siRNA knockdown of FOXA1, gene expression analysis, chromatin accessibility assays Nature genetics High 21151129
2019 FOXA1 class-1 wing-2 domain mutations enhance chromatin mobility and binding frequency, strongly transactivating a luminal androgen-receptor program. Class-2 C-terminal truncation mutations increase DNA affinity for dominant chromatin binding and promote WNT pathway-driven metastasis via TLE3 inactivation. Class-3 genomic rearrangements reposition a conserved regulatory element (FOXMIND) to drive FOXA1 or other oncogene overexpression. Aggregate cohort genomic analysis, functional assays in cell lines, live-cell imaging for chromatin mobility, ChIP-seq Nature High 31243372
2019 FOXA1 wing-2 domain mutations confer gain of function in pioneer activity, promoting exaggerated pro-luminal differentiation; R219 mutations at the DNA-contact residue block luminal differentiation and activate a neuroendocrine/mesenchymal program by preferentially binding a non-canonical DNA motif (GTAAAG/A instead of canonical GTAAAC/T). All tested mutants showed gain-of-function in prostate organoid proliferation. ATAC-seq, mouse prostate organoid proliferation assays, luciferase reporter assays, ChIP-seq, mutagenesis of 14 FOXA1 variants Nature High 31243370
2020 LSD1 (KDM1A) associates with FOXA1 and demethylates FOXA1 at lysine-270 (adjacent to wing-2 region of the DNA-binding domain), positively regulating FOXA1 chromatin binding. LSD1 inhibition globally disrupts FOXA1 chromatin binding and consequently androgen receptor binding and transcriptional output. Co-IP, in vitro demethylation assay, ChIP-seq, mutagenesis of K270, in vivo xenograft models Nature genetics High 32868907
2021 EZH2 methylates FOXA1 at lysine-295; this methylation is recognized by WD40-repeat protein BUB3, which recruits USP7 deubiquitinase to remove ubiquitination and stabilize FOXA1 protein, thereby promoting prostate cancer cell cycle gene regulation and growth. Co-IP, in vitro methylation assay, ubiquitination assay, ChIP-seq, cell proliferation assays, mutagenesis Science advances High 33827814
2023 SETD7 methylates FOXA1 at lysine-270 (the same site demethylated by LSD1), acting as the primary methyltransferase that disrupts FOXA1-mediated transcription, functioning as a tumor suppressor in castration-resistant prostate cancer. In vitro methylation assay, ChIP-seq, gene expression profiling, loss-of-function studies in prostate cancer cells Proceedings of the National Academy of Sciences of the United States of America High 37549269
2014 FOXA1 controls AR cistrome by opening chromatin around FKHD sites to recruit AR to low-affinity half-AREs. Too much FOXA1 creates excessive open chromatin that sequesters AR, reducing its availability; FOXA1 downregulation releases AR to permissively bind AREs genome-wide, enabling androgen-independent AR activity. Thus FOXA1 acts both as AR facilitator and inhibitor depending on expression level. ChIP-seq, FOXA1 knockdown/overexpression, gene expression analysis, androgen-independent growth assays Nature communications High 24875621
2016 FOXA1 associates with DNA repair complexes and is required for genomic targeting of DNA polymerase β (POLB). This FOXA1-DNA repair complex mediates local DNA demethylation at FOXA1-bound regions in a lineage-specific fashion, coupling DNA demethylation to transcriptional pioneering and estrogen receptor genomic targeting. Co-IP, ChIP-seq, whole-genome DNA methylome sequencing, FOXA1 overexpression/depletion, POLB ChIP-seq Nature genetics High 27500525
2016 FOXA1 induces TET1 expression by direct binding to its cis-regulatory elements, and physically interacts with TET1 protein through its CXXC domain. TET1 co-occupies FOXA1-dependent enhancers to mediate local DNA demethylation and H3K4 methylation in a feed-forward loop that potentiates FOXA1 recruitment. ChIP-seq, Co-IP, gene expression analysis, TET1 knockdown, bisulfite sequencing Nucleic acids research High 27257062
2014 SUMOylation of FOXA1 at K6, K389, and K267 regulates its nuclear mobility and transcriptional activity with AR. SUMO-2/3 modification occurs on endogenous FOXA1 in prostate cancer cells. FOXA1 slows nuclear mobility of agonist-bound AR; mutation of SUMO sites further retards FOXA1 mobility and enhances chromatin occupancy and AR-regulated PSA locus activity. SUMOylation assays in COS-1 cells, FRAP with mCherry-FOXA1 and EGFP-AR in HEK293, ChIP, gene expression in LNCaP cells, site-directed mutagenesis Molecular endocrinology High 25127374
2023 FOXA1 forms submicron-sized condensates through its N- and C-terminal intrinsically disordered regions (IDRs). Both IDRs enable FOXA1 to dissolve condensed chromatin. The DNA-binding capacity contributes to both condensate formation and condensed chromatin dissolution. IDRs are required for genome-wide binding and unpacking of condensed chromatin to regulate breast cancer cell proliferation and migration. Live-cell imaging, in vitro condensate assays, ATAC-seq, IDR deletion mutagenesis, functional proliferation/migration assays Molecular cell High 38101414
2021 FOXA1 is reprogrammed from androgen-receptor (AR) regulatory elements to neuroendocrine (NE)-specific regulatory elements in treatment-emergent neuroendocrine prostate cancer (NEPC). NEPC requires FOXA1 for proliferation and NE lineage gene expression. Ectopic expression of NE lineage TFs ASCL1 and NKX2-1 in prostate adenocarcinoma cells reprograms FOXA1 to NE regulatory elements. ChIP-seq (histone modifications), FOXA1 knockdown in NEPC, ectopic TF expression, patient-derived xenograft profiling Nature communications High 33785741
2019 FOXA1 overexpression drives genome-wide enhancer reprogramming through superenhancers in endocrine-resistant breast cancer, activating prometastatic transcriptional programs. HIF-2α was identified as the top high-FOXA1-induced superenhancer target mediating prometastatic effects. ChIP-seq, H3K27ac profiling, FOXA1 overexpression, gene expression analysis, functional migration/invasion assays, HIF-2α antagonist treatment Proceedings of the National Academy of Sciences of the United States of America High 31826955
2021 FOXA1 binds the STAT2 DNA-binding domain and suppresses STAT2 DNA-binding activity and interferon signaling gene expression in prostate and breast cancer cells, independently of FOXA1 transactivation activity and cancer-associated mutations. Co-IP, ChIP, gene expression analysis, FOXA1 overexpression/knockdown, IFN signaling reporter assays The Journal of clinical investigation High 34101624
2020 JQ1 directly interacts with FOXA1 and inactivates FOXA1 binding to its interacting repressors TLE3, HDAC7, and NFIC in a BET-independent manner, thereby blocking FOXA1-repressive function and activating invasion genes in prostate cancer. Co-IP, ChIP-seq, gene expression analysis, invasion assays, direct binding assay The Journal of clinical investigation High 31874106
2023 O-GlcNAcylation of FOXA1 at Thr432, Ser441, and Ser443 regulates FOXA1 protein stability and chromatin assembly, and reshapes the FOXA1 interactome by recruiting methyl-CpG binding protein 2 (MeCP2), redirecting FOXA1 chromatin-binding sites to adhesion-related gene loci to promote breast cancer metastasis. Mass spectrometry identification of O-GlcNAc sites, site-specific mutagenesis, Co-IP/interactome analysis, ChIP-seq, in vitro and in vivo metastasis assays Science advances High 37595040
2012 FoxA1 depletion causes significant redistribution of both androgen receptor (AR) and glucocorticoid receptor (GR) cistromes in prostate cancer cells in a cell-type- and receptor-specific manner. GR regulates many genes considered AR pathway-specific, and ligand-occupied GR attenuates AR-dependent transcription in the presence of androgen. ChIP-seq (AR and GR cistromes), FOXA1 knockdown, gene expression analysis Cancer research High 23269278
2009 FoxA1 forms a tripartite interaction with ERα and HDAC7 required for estrogen-mediated repression of RPRM (Reprimo). FoxA1 recruits to the RPRM promoter (marked by H3K4me1/me2) and interacts with HDAC7; estrogen treatment causes decreases in H3K4me1/me2 and release of RNA polymerase II from the RPRM promoter. Co-IP, ChIP, siRNA knockdown, gene expression analysis Molecular and cellular biology High 19917725
2024 NSD2 H3K36 dimethyltransferase is a requisite subunit of the AR/FOXA1 neo-enhanceosome in prostate cancer: tumor-specific AR enhancers bear a chimeric FOXA1:AR half-motif and critically depend on NSD2 activity. NSD2 inactivation disrupts >65% of the AR cistrome. ChIP-seq, NSD2 CRISPR/siRNA knockdown, PROTAC degradation, patient specimen enhancer mapping, gene expression analysis Nature genetics High 39251788
2024 Covalent small molecules bind FOXA1 at cysteine C258 within the forkhead DNA-binding domain in a DNA-dependent manner, rapidly remodeling FOXA1 pioneer activity by redistributing FOXA1 binding across the genome and changing chromatin accessibility, likely by relaxing canonical DNA-binding preference and strengthening interactions with suboptimal sequences near C258. Chemical proteomics, covalent ligand synthesis, ChIP-seq, ATAC-seq, motif analysis, site-directed mutagenesis Molecular cell High 39413792
2010 FOXA1 is required for hormone-induced mammary ductal invasion and terminal end bud formation, and is necessary for ERα expression in the mammary gland and breast cancer cell lines. Foxa1 null glands maintain GATA3 expression but lose ERα, demonstrating that FOXA1 regulates ERα expression but not GATA3 in a hierarchical manner. Foxa1 conditional knockout mouse model, immunohistochemistry, Western blot, siRNA knockdown in breast cancer cell lines Development (Cambridge, England) High 20501593
2018 FOXA1 induces homodimerization upon binding a compact palindromic DNA element (DIV - diverging half-sites) with strongly positive cooperativity; this homodimerization is constrained by precise half-site spacing and is required for full FOXA1-dependent transcriptional activity. FOXA1 DIV sites show increased chromatin accessibility upon PI3K inhibition. EMSA, reporter assays, ChIP-seq re-analysis, structural modeling, SNP allelic analysis Nucleic acids research Medium 29669022
2023 FOXA1 targets stable, DNase-resistant nucleosomes using lower nucleoplasmic diffusion and longer residence times to scan compact chromatin, distinct from SOX2 (higher diffusion, shorter residence) and HNF4A (which scans compact chromatin inefficiently). Both pioneer factors target stable nucleosomes whereas the non-pioneer HNF4A targets open chromatin. Single-molecule tracking (live-cell imaging), DNase-seq, comparison of multiple TFs Cell reports High 37405916
2016 FOXA1 and HDAC2 bind the Slug promoter and directly repress its transcription, acting downstream of NOR1. FOXA1 induces E-cadherin expression in mesenchymal breast cancer cells by suppressing Slug expression; FOXA1 knockdown in epithelial cells upregulates Slug and reduces E-cadherin protein. ChIP, Co-IP, luciferase reporter assay, siRNA knockdown, Western blot Oncotarget Medium 26934447 28867731
2016 FOXA1 acts as a dual-function transcription factor in ER-negative breast cancer: its repressive function on RELB is mediated by recruitment of corepressor TLE3. FOXA1 regulates ErbB2 signaling genes and is itself regulated transcriptionally by ErbB2 signaling components CREB1, c-Fos, and AP2α. ChIP, Co-IP, gene expression analysis, siRNA knockdown Neoplasia Medium 22577344
2021 NEDD4 E3 ubiquitin ligase physically interacts with FOXA1, triggers FOXA1 ubiquitination and proteasomal degradation, promoting colon cancer progression. Co-IP, ubiquitination assay, luciferase reporter, CHX chase for protein stability RNA biology Medium 33530829
2020 ZFP91 ubiquitin ligase ubiquitinates and destabilizes FOXA1 protein, promoting cancer cell growth; ZFP91 knockdown reduces FOXA1 polyubiquitination and enhances cellular sensitivity to chemotherapy in gastric cancer. Co-IP, ubiquitination assay, protein stability assay, ZFP91 knockdown Carcinogenesis Medium 31046116
2022 CREB5 physically interacts with FOXA1, AR, and other co-factors (GRHL2, HOXB13, TBX3, NFIC) at transcription regulatory elements active in metastatic castration-resistant prostate cancer; CREB5 overexpression extensively reprograms nuclear protein-protein interactions in response to enzalutamide and promotes AR-targeted therapy resistance. ChIP-seq, rapid immunoprecipitation and mass spectrometry of endogenous proteins (RIME), gene expression analysis eLife High 35550030
2014 FOXA1 physically interacts with androgen receptor (AR) in endometrial cancer cells. FOXA1 and AR co-bind the promoter and enhancer regions upstream of MYC. FOXA1 activates downstream AR targets (XBP1, MYC, ZBTB16, UHRF1) and promotes Notch pathway activation (Notch1, Hes1) in an AR-dependent manner to drive cell proliferation. Co-immunoprecipitation, ChIP-PCR, siRNA/shRNA knockdown, overexpression, xenograft model BMC cancer Medium 24512546
2022 FOXA1 functions as the primary orchestrator of alternative splicing dysregulation in prostate cancer by binding regulatory regions of splicing-related genes including HNRNPK and SRSF1, controlling trans-acting factor expression to calibrate alternative splicing via an exon definition mechanism. ChIP-seq, RNA-seq across 500 prostate cancer transcriptomes, functional knockdown, splicing assays Cell reports High 36170835
2020 FOXA1 wing-2 mutations in breast cancer display increased chromatin binding at ER loci upon estrogen stimulation and enhanced ER-mediated transcription without changes in chromatin accessibility. The breast cancer-specific SY242CS mutation opens distinct chromatin regions, activates an alternative cistrome and transcriptome, and structurally mediates stable binding to a non-canonical DNA motif. ATAC-seq, ChIP-seq, structural modeling, breast cancer patient cohort analysis, functional assays Cancer cell High 32888433
2024 FOXA1 mediates repression of NR3C1 (GR gene) expression via the corepressor TLE3. FOXA1 occupancy at pre-accessible chromatin restricts GR chromatin binding in prostate cancer cells; silencing FOXA1 potentiates GR chromatin binding and transcriptional activity counterintuitively to the classical pioneer factor model. ChIP-seq, siRNA knockdown of FOXA1, GR ChIP-seq, gene expression analysis Nucleic acids research High 38015476
2015 Nuclear receptor SHP inhibits transcriptional activation of BHMT and cystathionine γ-lyase by FOXA1, identified through ChIP showing SHP-FOXA1 interactions at these metabolic gene loci, establishing FOXA1 as a direct transcriptional activator of homocysteine metabolism genes regulated by SHP. ChIP, RNA-seq, metabolomics, SHP-null mouse model Gastroenterology Medium 25701738
2019 FOXA1 chromatin accessibility is regulated by DNA hypermethylation (silencing FOXA1 in basal bladder cancer) and by allelic loss; conditional inactivation of Foxa1 and PTEN in luminal/intermediate bladder cells in mice drives squamous differentiation and enhanced carcinogen sensitivity, establishing FOXA1 as a maintainer of urothelial identity. Conditional mouse knockout, bisulfite methylation analysis, DNMT inhibitor treatment, carcinogen challenge model Oncogene Medium 31636388
2017 FOXA1 directly binds the PLOD2 promoter and activates PLOD2 transcription in lung cancer cells, acting downstream of the EGFR-PI3K/AKT signaling axis to promote NSCLC metastasis through collagen reorganization. ChIP, luciferase reporter assay, siRNA knockdown, orthotopic metastasis mouse model Cell death & disease Medium 29072684
2019 Chromatin structure and nucleosome compaction dramatically influence TDG-mediated removal of 5-formylcytosine (5fC) from DNA. FOXA1 differentially regulates TDG activity on chromatin, providing direct experimental evidence that FOXA1 pioneer factor activity modulates active DNA demethylation through TDG at enhancers. In vitro reconstituted nucleosome array assays with chemically defined 5fC, TDG activity assay, FOXA1 addition experiments Journal of the American Chemical Society High 31460763
2017 Twist1 binds to the FOXA1 proximal promoter and recruits the NuRD transcriptional repressor complex to de-acetylate H3K9 and repress RNA polymerase II recruitment, thereby silencing FOXA1 expression. Twist1 also inhibits AP-1 recruitment to the FOXA1 promoter. Silencing of FOXA1 by Twist1 is largely responsible for Twist1-induced migration, invasion and metastasis. ChIP, Co-IP, luciferase reporter assay, xenograft mouse model, gain/loss-of-function experiments Oncogene High 27524420
2017 FOXA1 inhibits PIK3R1 (PI3Kp85) transcription directly, suppressing PI3K/Akt signaling and hepatocellular carcinoma cell viability and motility in male patients. ChIP, luciferase reporter, gain/loss-of-function in HCC cell lines, clinical sample analysis Journal of experimental & clinical cancer research Medium 29208003
2005 Foxa1 and Foxa2 have compensatory roles in lung morphogenesis; combined deletion inhibits cell proliferation, epithelial differentiation, and branching. Foxa1 and Foxa2 regulate Shh and Shh-dependent genes in respiratory epithelial cells, influencing mesenchymal gene expression required for branching. Foxa2 conditional knockout / Foxa1 null double-mutant mouse model, morphological analysis, gene expression The Journal of biological chemistry High 15668254
2014 Conditional deletion of both Foxa1 and Foxa2 (but not Foxa2 alone) from adult dopamine neurons causes striatal dopamine depletion, loss of DAT and AADC expression, decline of Aldh1a1, and progressive dopamine neuron loss resembling Parkinson's disease. Tamoxifen-inducible tissue-specific CreERT2 knockout (DATCreERT2), immunohistochemistry, dopamine HPLC, behavioral assays Frontiers in cellular neuroscience Medium 25249938
2021 Foxa1 and Foxa2 are required to regulate RNA splicing during positive selection of mouse T cells; their deletion reduces CD4SP and CD8SP T cell development. They control expression of splicing factors (Mbnl1, Sf3b1, Hnrnpa1, etc.) and alter >850 differentially used exons. Conditional double knockout mouse model, RNA-seq splicing analysis, gene expression Development (Cambridge, England) Medium 34323272
2015 FOXA1 depletion abrogates ~41% of the AR-variant (AR-V) transcriptome in CRPC cells and attenuates AR-V chromatin binding at co-regulated genes, demonstrating that AR-Vs depend on FOXA1 as a pioneer factor for sustaining a pro-proliferative gene signature. FOXA1 knockdown, RNA-seq/gene expression profiling, ChIP, cell proliferation assays in CWR22Rv1 Oncotarget Medium 26336819
2015 EAF2 co-immunoprecipitates with FOXA1 and downregulates FOXA1 protein levels; EAF2 knockdown enhances FOXA1 protein expression and AR target gene expression, cell proliferation, and migration in prostate cancer cells, which is reversed by FOXA1 knockdown. Co-IP, protein stability assay, C. elegans RNAi screen, siRNA knockdown, luciferase reporter, BrdU proliferation assay The Prostate Medium 25808853
2014 FOXA1 repression in BRCA1-deficient breast cancer is mediated by EZH2-dependent H3K27me3 deposition and DNMT-mediated promoter methylation. BRCA1 binds EZH2 and negatively regulates its methyltransferase activity; BRCA1 loss enables EZH2/DNMT1/3a/3b-mediated epigenetic silencing of FOXA1. ChIP, Co-IP, siRNA knockdown of BRCA1 and EZH2, 5-aza-dC treatment, GSK126 (EZH2 inhibitor) treatment, Brca1-deficient mouse mammary epithelial cells Oncogene High 25531315
2017 Pioneer factors FOXA1 and FOXA2 are required for initiation of NKX2-1-negative mucinous lung adenocarcinomas and for activation of their gastric differentiation program. Sequential in vivo recombination shows that FoxA1/2 loss in established KRAS-driven neoplasia drives keratinizing squamous cell carcinoma, demonstrating that FOXA1/2 maintain gastric identity and suppress squamous identity downstream of NKX2-1 loss. Conditional mouse knockout, sequential in vivo recombination, gene expression, IHC eLife High 30475207
2022 FoxA1/2 knockout in NKX2-1-positive KRAS-driven LUAD causes collapse of a dual pulmonary/gastrointestinal identity state by inducing aberrant NKX2-1 genomic relocalization that actively inhibits tumorigenesis and drives alternative non-proliferative identity programs. Conditional CRISPR/genetic knockout in GEMMs and human cell lines, ChIP-seq, RNA-seq, ATAC-seq Developmental cell High 35835117
2010 Foxa2 directly binds genomic regions of Gli2 and likely regulates Gli2 expression to attenuate Shh signaling in the ventral midbrain. Foxa1 and Foxa2 positively regulate Shh expression and negatively regulate Gli2 expression to specify ventral midbrain progenitor identity. ChIP, conditional knockout in mice (Wnt1cre;Foxa2flox/flox), gain- and loss-of-function studies Mechanisms of development Medium 21093585
2017 Pioneer factors FOXA1 and FOXA2 assist selective glucocorticoid receptor (GR) signaling by enabling GR recruitment to the LEFTY1 promoter in human endometrial cells; glucocorticoid-mediated GR recruitment to LEFTY1 depends on FOXA1 and FOXA2, and E2 antagonizes this by reducing recruitment of GR, FOXA1, FOXA2, and active polymerase 2. ChIP, siRNA knockdown of FOXA1/FOXA2, luciferase reporter, gene expression analysis in primary and immortalized endometrial cells Endocrinology Medium 28938408
2022 FOXA1 repression in bladder cancers with squamous differentiation leads to loss of PD-L1 expression and intrinsic immunotherapy resistance; FOXA1 coordinately regulates lineage identity and immune checkpoint expression in urothelial cells. Integrated genomic analysis of human bladder cancer specimens, phylogenetic analysis, FOXA1 expression correlation with PD-L1 and immunotherapy response data Nature communications Medium 36323682
2022 FOXA1 binds the imprinting control region of IGF2 and interacts with DNMT1, initiating DNMT1-mediated loss of imprinting (LOI) of IGF2 and autocrine IGF2 secretion in lung adenocarcinoma cells; FOXA1 also suppresses GBA1 expression through IGF2-enhanced ubiquitination to inhibit autophagic cell death. ChIP, Co-IP, siRNA knockdown, IGF2 neutralization, IGF1R inhibitor treatment, xenograft model Cell death & disease Medium 35974000

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2010 FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature genetics 690 21151129
2019 Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature 234 31243372
2005 Compensatory roles of Foxa1 and Foxa2 during lung morphogenesis. The Journal of biological chemistry 224 15668254
2019 FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature 219 31243370
2007 FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clinical cancer research : an official journal of the American Association for Cancer Research 206 17671124
2010 FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development (Cambridge, England) 199 20501593
2012 FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer research 189 23269278
2004 Immunohistochemical localization of Foxa1 and Foxa2 in mouse embryos and adult tissues. Gene expression patterns : GEP 186 15567715
2012 FOXA1: a transcription factor with parallel functions in development and cancer. Bioscience reports 176 22115363
2014 Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nature communications 160 24875621
2011 FOXA1: master of steroid receptor function in cancer. The EMBO journal 159 21934649
2020 Pioneer of prostate cancer: past, present and the future of FOXA1. Protein & cell 131 32946061
2016 Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene 129 27524420
2021 Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nature communications 126 33785741
2019 FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proceedings of the National Academy of Sciences of the United States of America 123 31826955
2020 Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nature genetics 104 32868907
2020 FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer cell 96 32888433
2017 PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC. Cell death & disease 81 29072684
2021 FOXA1 overexpression suppresses interferon signaling and immune response in cancer. The Journal of clinical investigation 79 34101624
2014 Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance. Frontiers in cellular neuroscience 70 25249938
2017 LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in osteosarcoma by regulating miR-212-3p/FOXA1 axis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 68 29793327
2009 Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. Molecular and cellular biology 68 19917725
2018 FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. eLife 65 30475207
2020 Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1. The Journal of clinical investigation 62 31874106
2015 GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas. Human pathology 62 26527523
2021 Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer. Science advances 61 33827814
2014 FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer. BMC cancer 60 24512546
2015 Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes & diseases 59 26114156
2014 Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. International journal of biological sciences 59 24948874
2016 Nucleation of DNA repair factors by FOXA1 links DNA demethylation to transcriptional pioneering. Nature genetics 56 27500525
2016 FOXA1 defines cancer cell specificity. Science advances 55 27034986
2016 FOXA1 potentiates lineage-specific enhancer activation through modulating TET1 expression and function. Nucleic acids research 55 27257062
2021 FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer. Cancers 52 34680352
2010 Foxa1 and Foxa2 positively and negatively regulate Shh signalling to specify ventral midbrain progenitor identity. Mechanisms of development 52 21093585
2020 Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nature communications 51 31974375
2024 FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer. Cell death discovery 48 38605023
2015 Interactions Between Nuclear Receptor SHP and FOXA1 Maintain Oscillatory Homocysteine Homeostasis in Mice. Gastroenterology 48 25701738
2017 FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients. Journal of experimental & clinical cancer research : CR 47 29208003
2012 Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia (New York, N.Y.) 46 22577344
2023 FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer. Science advances 45 37595040
2023 hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Molecular cancer 44 38044421
2023 FOXA1 forms biomolecular condensates that unpack condensed chromatin to function as a pioneer factor. Molecular cell 41 38101414
2022 FoxA1 and FoxA2 control growth and cellular identity in NKX2-1-positive lung adenocarcinoma. Developmental cell 41 35835117
2015 FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Oncotarget 37 26336819
2022 FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation. Nature communications 36 36323682
2014 FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer. Oncogene 36 25531315
2017 MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1. Acta pharmacologica Sinica 32 28816236
2015 MicroRNA-212 inhibits hepatocellular carcinoma cell proliferation and induces apoptosis by targeting FOXA1. OncoTargets and therapy 32 26347321
2022 FOXA1 regulates alternative splicing in prostate cancer. Cell reports 31 36170835
2021 NEDD4 triggers FOXA1 ubiquitination and promotes colon cancer progression under microRNA-340-5p suppression and ATF1 upregulation. RNA biology 31 33530829
2014 Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation. Molecular endocrinology (Baltimore, Md.) 31 25127374
2024 Redirecting the pioneering function of FOXA1 with covalent small molecules. Molecular cell 30 39413792
2020 FOXA1 Suppresses the Growth, Migration, and Invasion of Nasopharyngeal Carcinoma Cells through Repressing miR-100-5p and miR-125b-5p. Journal of Cancer 29 32201519
2019 Dysregulation of miR-431 and target gene FOXA1 in intestinal tissues of infants with necrotizing enterocolitis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 28 30624964
2018 miR-132 Targets FOXA1 and Exerts Tumor-Suppressing Functions in Thyroid Cancer. Oncology research 28 29523221
2018 Impact of OGT deregulation on EZH2 target genes FOXA1 and FOXC1 expression in breast cancer cells. PloS one 28 29864144
2015 Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial. Future oncology (London, England) 28 26260807
2023 Celastrol inhibits gastric cancer cell proliferation, migration, and invasion via the FOXA1/CLDN4 axis. Toxicology research 27 37397926
2021 The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancer. Current opinion in structural biology 27 34225008
2019 Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer. Oncogene 27 31636388
2016 Significance of the NOR1-FOXA1/HDAC2-Slug regulatory network in epithelial-mesenchymal transition of tumor cells. Oncotarget 27 26934447
2023 Different chromatin-scanning modes lead to targeting of compacted chromatin by pioneer factors FOXA1 and SOX2. Cell reports 26 37405916
2021 MicroRNA-100 inhibits breast cancer cell proliferation, invasion and migration by targeting FOXA1. Oncology letters 26 34671430
2017 The transcription factor FOXA1 induces epithelial ovarian cancer tumorigenesis and progression. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 26 28488543
2021 Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility. Nature communications 25 34518541
2018 Frequent mutation of the FOXA1 untranslated region in prostate cancer. Communications biology 25 30272002
2017 Role of transcription factor FOXA1 in non‑small cell lung cancer. Molecular medicine reports 25 29115441
2015 FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells. The Prostate 25 25808853
2024 NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis. Nature genetics 24 39251788
2018 MiR-760 enhances TRAIL sensitivity in non-small cell lung cancer via targeting the protein FOXA1. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 24 29665655
2010 Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model. Oncology reports 24 20878115
2022 CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies. eLife 23 35550030
2017 FOXA1 Induces E-Cadherin Expression at the Protein Level via Suppression of Slug in Epithelial Breast Cancer Cells. Biological & pharmaceutical bulletin 23 28867731
2014 MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer. Oncotarget 23 25071007
2019 Chromatin Structure and the Pioneering Transcription Factor FOXA1 Regulate TDG-Mediated Removal of 5-Formylcytosine from DNA. Journal of the American Chemical Society 22 31460763
2014 Switch in FOXA1 status associates with endometrial cancer progression. PloS one 22 24849812
2023 FOXA1 in prostate cancer. Asian journal of andrology 21 36018068
2017 A novel FOXA1/ESR1 interacting pathway: A study of Oncomine™ breast cancer microarrays. Oncology letters 21 28789340
2017 Overexpression of FOXA1 inhibits cell proliferation and EMT of human gastric cancer AGS cells. Gene 21 29129808
2020 HDAC2-mediated proliferation of trophoblast cells requires the miR-183/FOXA1/IL-8 signaling pathway. Journal of cellular physiology 19 33164209
2019 FOXA1+ regulatory T cells: A novel T cell subset that suppresses antitumor immunity in lung cancer. Biochemical and biophysical research communications 19 31036318
2018 Transcriptome analyses reveal FOXA1 dysregulation in mammary and extramammary Paget's disease. Human pathology 19 29630912
2021 FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression. Journal of cancer research and clinical oncology 18 34258652
2022 Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer. Cell death & disease 17 36050295
2021 The pioneer transcription factors Foxa1 and Foxa2 regulate alternative RNA splicing during thymocyte positive selection. Development (Cambridge, England) 17 34323272
2020 FOXA1-induced circOSBPL10 potentiates cervical cancer cell proliferation and migration through miR-1179/UBE2Q1 axis. Cancer cell international 17 32831649
2019 SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer. The Prostate 17 31090082
2018 DNA-mediated dimerization on a compact sequence signature controls enhancer engagement and regulation by FOXA1. Nucleic acids research 17 29669022
2016 FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations. Cancer science 17 26708273
2023 SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1. Proceedings of the National Academy of Sciences of the United States of America 16 37549269
2022 FOXA1 prevents nutrients deprivation induced autophagic cell death through inducing loss of imprinting of IGF2 in lung adenocarcinoma. Cell death & disease 16 35974000
2020 FOXA1-induced LINC01207 facilitates head and neck squamous cell carcinoma via up-regulation of TNRC6B. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 16 32450521
2019 Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer. Molecular biology reports 16 30941644
2020 The ubiquitinase ZFP91 promotes tumor cell survival and confers chemoresistance through FOXA1 destabilization. Carcinogenesis 15 31046116
2024 Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer. Nucleic acids research 14 38015476
2023 FOXA1/MND1/TKT axis regulates gastric cancer progression and oxaliplatin sensitivity via PI3K/AKT signaling pathway. Cancer cell international 14 37817120
2017 Pioneer Factors FOXA1 and FOXA2 Assist Selective Glucocorticoid Receptor Signaling in Human Endometrial Cells. Endocrinology 14 28938408
2022 A Transcriptional Link between HER2, JAM-A and FOXA1 in Breast Cancer. Cells 13 35203384
2020 IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells. Oncotarget 13 32655839
2019 Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer. BMC cancer 13 31888566